Minaris Regenerative Medicine GmbH
Booth number: 180-10
www.rm.minaris.com/en/
About us
Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies (CGT). We offer our clients high value clinical and commercial manufacturing services, development solutions and technologies. We are pioneers in the field with over 20 years' experience providing outstanding quality and reliability. Our facilities in the US, Europe and Asia allow us to supply patients worldwide with life-changing therapies.
Minaris has extensive experience in process development and GMP manufacturing of clinical and commercial cell therapy products, including autologous and allogeneic cells, primary and genetically modified, mesenchymal stromal cells (MSC), hematopoietic stem cells (HSC), lymphocytes, monocytes, dendritic cells, NKs, TILs, CAR-T and iPSCs.
GMP manufacturing of autologous and allogeneic cell therapy products, genetically modified and native cells, mesenchymal stell cells (MSC), hematopoietic stem cells (HSC), lymphocytes and monocytes, NK cells, dendritic cells, CAR-T and iPSCs technologies.
Process development, analytic development for cell and gene therapies.
Advanced Therapy Medicinal Products (ATMP), Regenerative Medicine, cell culture.
Compliant to EMA (EU) and FDA (USA) regulatory environments.
3D bioreactor technology for cell culture.
Batch certification by Qualified Person (QP) for cell and gene therapies in the European Union (EMA).
Address
Haidgraben 5
85521 Ottobrunn
Germany
E-mail: info@rm.minaris.de
Phone: +49 89 700 96080
Internet: www.rm.minaris.com/en/
75 Commerce Drive
NJ 07401 Allendale
United States
Phone: +1 1010 101
4F, Shibusawa ABC Bldg #1
1 Ebisu-chou, Kanagawa-ku,
221-0024 Yokohama-shi, Kanagawa
Japan
Phone: +81 43582
Contact person:
Dr. Almut Windhager
Senior Manager Communications
E-mail: contact@rm.minaris.de
Phone: +49 89 700 96080
Products & Services
GMP manufacturing of autologous and allogeneic cell therapy products, genetically modified and native cells, mesenchymal stell cells (MSC), hematopoietic stem cells (HSC), lymphocytes and monocytes, NK cells, dendritic cells, CAR-T and iPSCs technologies.
Process development, analytic development for cell and gene therapies.
Advanced Therapy Medicinal Products (ATMP), Regenerative Medicine, cell culture.
Compliant to EMA (EU) and FDA (USA) regulatory environments.
3D bioreactor technology for cell culture.
Batch certification by Qualified Person (QP) for cell and gene therapies in the European Union (EMA).
Consulting services for all stages of cell therapy development.